3-methyl-4-{3-[3-(methylsulfonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline | 1020734-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-methyl-4-{3-[3-(methylsulfonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline
• 英文别名: 3-Methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline；3-methyl-4-[3-(3-methylsulfonylphenoxy)phenyl]-8-(trifluoromethyl)quinoline
• CAS: 1020734-89-7
• 化学式: C₂₄H₁₈F₃NO₃S
• 分子量: 457.473
• InChiKey: ZDUOYBOFMKORCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-methyl-4-{3-[3-(methylsulfonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline 、 methyloxirane 在 仲丁基锂 作用下， 以 乙醚 、 环己烷 、 四氢呋喃 为溶剂， 反应 0.25h， 生成 4-[(3-{3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}phenyl)sulfonyl]butan-2-ol
  参考文献：
  名称：

  WO2008/49047

  摘要：

  公开号：

文献信息

• Treatment and diagnosis of melanoma
  申请人：The Rockefeller University

  公开号：US10543183B2

  公开（公告）日：2020-01-28

  The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

  本发明公开了用于诊断和治疗黑色素瘤的新型制剂和方法。还公开了相关的阵列、试剂盒和筛选方法。
• QUINOLINE COMPOUNDS
  申请人：Wyeth

  公开号：EP2074098A2

  公开（公告）日：2009-07-01
• TREATMENT OF DRUG RESISTANT CANCER
  申请人：ROCKEFELLER UNIVERSITY (THE)

  公开号：US20150073053A1

  公开（公告）日：2015-03-12

  The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
• TREATMENT AND DIAGNOSIS OF MELANOMA
  申请人：The Rockefeller University

  公开号：US20160331726A1

  公开（公告）日：2016-11-17

  The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
• METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
  申请人：The Rockefeller University

  公开号：US20190029984A1

  公开（公告）日：2019-01-31

  The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.